Prophylactic pelvic nodal RT vs only prostate bed irradiation in patients with prostatic cancer
PO-1368
Abstract
Prophylactic pelvic nodal RT vs only prostate bed irradiation in patients with prostatic cancer
Authors: Taiusha Fuentes1, Elisa Calistri1, Aldo Sainato1, Bruno Manfredi1, Fabrizio Matteucci1, Riccardo Morganti1, Francesco Pasqualetti1, Fabiola Paiar1
1University Hospital of Pisa, Oncological Radiotherapy, Pisa, Italy
Show Affiliations
Hide Affiliations
Purpose or Objective
Purpose: In patients with
prostate cancer, a little known aspect in the post-operative setting is whether
irradiating the lymph node chains instead of the prostate bed alone can confer
an additional benefit in terms of disease recurrence. Purpose of our study was
to demonstrate an improvement of biochemical control by post-operative nodal
irradiation respect to prostate-only irradiation in patients with prostate
cancer undergoing radical prostatectomy.
Material and Methods
Material and Methods: We evaluated 404 patients with prostate cancer treated with adjuvant
or salvage RT at Radiotherapy Unit of Pisa University Hospital from January
2011 to December 2011. All patients were treated using VMAT radiotherapy. ADT
was administered to patients with high-risk prostate cancer in accordance with
EAU guidelines. We studied biochemical progression free survival for each
category of risk according to the NCCN classification. We did multivariate
analysis of Progression Free Survival factors risk by step-wise method.
Results
Results: Evaluating all
patients with a median follow-up of 62 months, we did not found statistically
significant advantage (p=0,77) by nodal radiotherapy; however, in the analysis
of sub categories, we found a trend toward a significant advantage in
prophylactic nodal irradiation in 140 patients with low and intermediate risk
class (p=0,056).
Conclusion
Conclusion: Our study highlights how the whole pelvic
nodal prophylactic radiation therapy does not offer an additional benefit in
all patients, but only in selected patients with low-intermediate prostate
cancer. Larger and prospective studies are needed to confirm our results.